What is Tagomics?
Founded in 2020, Tagomics operates at the intersection of advanced data science and molecular biology. The company has developed a proprietary platform designed to provide deep, actionable insights into disease mechanisms, enabling more accurate and timely diagnostic outcomes. By leveraging high-throughput genomic data, Tagomics addresses the urgent need for sophisticated tools that can translate complex biological information into clinical utility. Its market position is bolstered by its strategic location in the Cambridge biotech cluster, allowing for seamless collaboration with leading academic institutions and industry partners. The company's focus on multi-omics integration positions it as a transformative force in the diagnostic landscape, moving beyond traditional single-marker testing toward a holistic view of patient health.
How much funding has Tagomics raised?
Tagomics has raised a total of $8.5M across 1 funding round:
Other Financing Round
$8.5M
Other Financing Round (2024): $8.5M with participation from Illumina Ventures, IQ Capital, and Calculus Capital
Key Investors in Tagomics
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
IQ Capital
IQ Capital is a venture capital firm based in Cambridge and London that invests in deep-tech across sectors including machine learning, AI, and data-focused propositions.
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology and healthcare businesses.
What's next for Tagomics?
The recent infusion of capital is expected to catalyze the next phase of Tagomics' growth trajectory, specifically targeting the scaling of its diagnostic platform and the expansion of its clinical validation studies. As the company transitions from early-stage development to a more mature enterprise-level operation, the focus will likely shift toward commercializing its diagnostic suite and forging strategic partnerships with global biopharmaceutical entities. By utilizing this latest financing, Tagomics aims to refine its algorithmic capabilities and broaden its diagnostic reach, ultimately striving to improve patient outcomes through data-driven precision health. The backing from specialized deep-tech and life science investors provides not only the necessary liquidity but also the institutional expertise required to navigate the complex regulatory and commercial hurdles inherent in the genomics market.
See full Tagomics company page
